Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-894 · 2 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | ABT-894 1 mg BID |
| B | EXPERIMENTAL | ABT-894 2 mg BID |
| C | EXPERIMENTAL | ABT-894 4 mg BID |
| D | PLACEBO_COMPARATOR | - |
| E | ACTIVE_COMPARATOR | Duloxetine 60 mg QD |
| Name | Type | Description |
|---|---|---|
| ABT-894 | DRUG | 6 mg BID tablets, 8 weeks of treatment |
| placebo | DRUG | BID tablets, 8 weeks of treatment |
| Duloxetine | DRUG | Duloxetine 60 mg QD throughout treatment period |
Inclusion Criteria: * Males and females, age 18 to 75 * If female, must be of non-childbearing potential or practicing birth control * Has diabetes mellitus (Type 1 or 2) and a diagnosis of painful distal symmetric diabetic polyneuropathy * Has had pain from distal symmetric diabetic polyneuropathy...
ABT-894 is an investigational small molecule being developed for diabetic neuropathic pain and diabetic neuralgia. It is a neurology therapeutic that has been studied in Phase 2 clinical trials for these painful diabetic neuropathy conditions.
ABT-894 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is an investigational small molecule in Phase 2 clinical development for diabetic neuropathic pain.
ABT-894 is in Phase 2 clinical development. It is an investigational drug, not yet approved by the FDA, and has completed Phase 2 trials for diabetic neuropathic pain and diabetic neuralgia.
ABT-894 has completed two Phase 2 clinical trials. NCT00507936 enrolled 280 participants with diabetic neuropathic pain across the US, Canada, France, Germany, Italy, Mexico, and Puerto Rico. NCT00548925 enrolled 124 participants in the US, Czechia, France, Germany, Italy, Spain, and the UK.
ABT-894 is the primary name for this investigational compound. No alternative names have been disclosed for this drug in the clinical trial data.